Relationships between blood product exposure and immunological abnormalities in English haemophiliacs.
Lee. C A CA; Bofill. M M; Janossy. G G; Thomas. H C HC; Rizza. C R CR; Kernoff. P B PB
Key Findings
- Heavier exposure to clotting factor concentrates correlates with immune abnormalities (low T4/T8 ratio, high T8 count).
- Serum alpha‑1‑thymosin levels were frequently elevated in these patients, while beta‑2‑microglobulin stayed normal.
- The way clotting factors are processed and the amount used likely cause the immune changes, not the original donor plasma.
Practical Outcomes
- For most biohackers, this research offers little direct guidance on using thymosin‑alpha‑1 for health or performance. It mainly highlights that blood‑derived products can affect immune markers, suggesting caution with unfiltered blood components, but does not provide actionable dosing or protocol advice for thymosin‑alpha‑1 supplementation.
Summary
The study looked at English haemophilia patients who got clotting factor concentrates from blood products and found they often had immune system quirks, like altered T‑cell ratios and higher levels of a protein called alpha‑1‑thymosin. These changes were linked to how much blood product they received, not the donor source, and were more common in adults and those with haemophilia A.
Abstract
Amongst 160 English haemophiliacs treated with clotting factor concentrates, abnormalities of T lymphocyte subset distribution (characterized by low T4/T8 ratios and high total T8 counts), low in vitro phytohaemagglutinin stimulation and raised serum IgG levels, were more common in patients with haemophilia A than B, in patients who had received heavier blood product exposure, and in adults rather than children. A slight reduction in lymphocyte and platelet counts was found in 26% and 17% of patients. In the sample of patients tested, serum alpha 1-thymosin levels were often raised, but beta 2-microglobulin levels were usually normal. Fractionation procedures used to prepare clotting factor concentrates, and the amounts of concentrate used, are more likely to be causally related to these immunological abnormalities than the origins of source donor plasmas.
Study Information
pubmed
1985
1985-05-01T00:00:00.000Z
10.1111/j.1365-2141.1985.tb07397.x
17
48